Hematopoietic growth factor mimetics: from concept to clinic

Area of Science:

• Biochemistry
• Pharmacology
• Biotechnology

Background:

• Hematopoietic growth factor (HGF) mimetics present therapeutic advantages, including reduced cost and oral availability.
• Small chemical compounds as HGF mimetics often avoid immunogenic responses due to structural dissimilarity to native cytokines.

Purpose of the Study:

• To summarize approaches for achieving potency and stability in small peptide agonists for erythropoietin (EPO) and thrombopoietin (TPO) receptors.
• To compare screening, translational, and clinical issues of approved TPO mimetics (romiplostim, eltrombopag) and an EPO mimetic (Hematide).
• To discuss future potential for isolating growth factor (GF) mimetics.

Main Methods:

• Review of literature on HGF mimetic development, focusing on EPO and TPO receptor agonists.
• Comparative analysis of screening strategies and clinical data for selected TPO and EPO mimetics.
• Discussion of translational challenges and clinical utility.

Main Results:

• Small molecule HGF mimetics demonstrate potential for reduced cost and improved oral bioavailability.
• Development of potent and stable peptide agonists for EPO and TPO receptors faces translational hurdles.
• Romilostim, eltrombopag, and Hematide represent key advancements in TPO and EPO mimetic therapy.

Conclusions:

• HGF mimetics, especially small molecules, offer promising therapeutic avenues with reduced immunogenicity and improved patient compliance.
• Overcoming translational challenges is crucial for the clinical success of EPO and TPO receptor agonists.
• Continued research into GF mimetic isolation holds significant potential for future therapeutic innovations.